November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Manni Mohyuddin: The results of the GEM-CESAR trial are a stunning verdict against early intervention in SMM
Jul 25, 2024, 00:44

Manni Mohyuddin: The results of the GEM-CESAR trial are a stunning verdict against early intervention in SMM

Manni Mohyuddin shared on X:

“The GEM-CESAR trial of a super aggressive approach to SMM (KRD>Transplant>KR>Len) just got published.

The results are a stunning verdict against early intervention in SMM, despite the way the results are potrayed. Here is a peer review and critical appraisal of this.”

Image

Authors: María-Victoria Mateos, Joaquin Martínez-López, Paula Rodriguez Otero, Verónica González-Calle, Marta Sonia Gonzalez, Albert Oriol, Norma C. Gutiérrez, Rafael Ríos-Tamayo, Laura Rosiñol, Miguel Angel Alvarez Rivas, Joan Bargay, Ana Pilar Gonzalez-Rodriguez, Adrián Alegre, Fernando Escalante, María Belén Iñigo Rodríguez, Javier De La Rubia, Ana Isabel Teruel, Felipe de Arriba, Luis Palomera, Miguel T. Hernández, Javier Lopez Jiménez, Marta Reinoso-Segura, Aránzazu García Mateo, Enrique M. Ocio, Bruno Paiva, Noemi Puig, M. Teresa Cedena, Joan Bladé, Juan Jose Lahuerta, Jesus F. San-Miguel

Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance

Source: Manni Mohyuddin/X

Dr. Manni Mohyuddin is an Assistant Professor at the Huntsman Cancer Institute, University of Utah, specializing in oncology. He is mainly interested in myeloma, supportive care, end-of-life management, and implementing cost-effective, evidence-based treatment strategies.